Suzhou Ribo Life Science Co., Ltd. clinical trials
The registry lists 15 studies whose lead sponsor is Suzhou Ribo Life Science Co., Ltd. or one of 1 company grouped under it. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.
Our grouping of 2 registry names, not the registry’s. See them and correct one ↓
- 15studies on the registry
- 6open to participants now
- 5reach primary completion within a year
Get an email when these change. Save the Suzhou Ribo Life Science Co., Ltd. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 5 programmes
Each counted once: 5 with a study Suzhou Ribo Life Science Co., Ltd. leads registered in the last two years.
The 5 programmes — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or primary completion.
Not counted: 1 approved drug Suzhou Ribo Life Science Co., Ltd. gives alongside its own in its studies — apixaban (with vortosiran). Our rule: a drug many companies test, in every study Suzhou Ribo Life Science Co., Ltd. led of it in the last two years beside a drug of its own.
New in the registry
A programme's first Suzhou Ribo Life Science Co., Ltd. study in the last 90 days, by the day it was submitted.
- Sep 17vortosiran · Atrial FibrillationPhase 2
Moved up a phase
Suzhou Ribo Life Science Co., Ltd.'s first study at a higher phase in the last 90 days, of a programme already under way.
- Oct 13RBD1119 · Coronary Artery Diseaseto Phase 2
“Registry” is the highest phase of Suzhou Ribo Life Science Co., Ltd.’s own registered studies; Suzhou Ribo Life Science Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
What it is testing
The drugs Suzhou Ribo Life Science Co., Ltd.’s studies test, most open studies first — 4 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
Coming up
5 of Suzhou Ribo Life Science Co., Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- 1MMay
- JJun
- 1JJul
- 1AAug
- 2SSep
- OOct
- NNov
All 5
- May 2027Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed DyslipidemiaRBD5044 · NCT06797401
- Jul 2027Vortosiran for VTE PreventionNCT07850453
- Aug 2027Phase I Trial of RBD4059 in Chinese Healthy ParticipantsRBD4059 · NCT07930767
- Sep 2027RBD1119 in Coronary Artery Disease (CAD)NCT07884136
- Sep 2027First-in-human Trial of RBD2080 in Healthy ParticipantsNCT07869940
Add all 5 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 15, 2026.
Newly registered2
- Phase I Trial of RBD4059 in Chinese Healthy ParticipantsNov 12, 2026NCT07930767
- RBD1119 in Coronary Artery Disease (CAD)Oct 20, 2026NCT07884136
All 15 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 21
- 22
- 23
- 24
- 25
- 526
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Suzhou Ribo Life Science Co., Ltd..
- Suzhou Ribo Life Science Co. Ltd.9 studiesSame company
Something wrong?
- Ribocure Pharmaceuticals AB6 studies →Subsidiary
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 15 of 15.
- Phase I Trial of RBD4059 in Chinese Healthy ParticipantsNot yet recruitingNCT07930767Phase 1
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.
- RBD1119 in Coronary Artery Disease (CAD)Not yet recruitingNCT07884136Phase 2
Sponsor listed in the registry: Ribocure Pharmaceuticals AB
- First-in-human Trial of RBD2080 in Healthy ParticipantsRecruitingNCT07869940Phase 1
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.
- Vortosiran in Atrial FibrillationNot yet recruitingNCT07870889Phase 2
Sponsor listed in the registry: Ribocure Pharmaceuticals AB
- Vortosiran for VTE PreventionNot yet recruitingNCT07850453Phase 2
Sponsor listed in the registry: Ribocure Pharmaceuticals AB
- Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed DyslipidemiaRecruitingNCT06797401Phase 2
Sponsor listed in the registry: Ribocure Pharmaceuticals AB
- Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD1119 in Healthy ParticipantsActive, not recruitingNCT07042594Phase 1
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.
- Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of RBD1016 in Participants With Chronic Hepatitis DActive, not recruitingNCT06649266Phase 2
Sponsor listed in the registry: Ribocure Pharmaceuticals AB
- A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy SubjectsCompletedNCT05653037Phase 1
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.
- A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants With Stable Coronary Artery DiseaseCompletedNCT06717074Phase 2
Sponsor listed in the registry: Ribocure Pharmaceuticals AB
- A Study of RBD1016 in CHB ParticipantsCompletedNCT05961098Phase 2
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.
- A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022CompletedNCT05912296Phase 1
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.
- A Single and Repeated Dose Escalation of RBD1016 in Subjects with Chronic Hepatitis B Virus (HBV) InfectionCompletedNCT05017116Phase 1
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.
- A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044CompletedNCT05539651Phase 1
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.
- A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016CompletedNCT04685564Phase 1
Sponsor listed in the registry: Suzhou Ribo Life Science Co. Ltd.